Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

In Partnership With:

Partner | Cancer Centers | <b>MD Anderson</b>

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Yi Lin, MD, PhD, hematologist, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

CD19-targeted CAR T-cell therapy has established a role in various leukemias and lymphomas. However, in multiple myeloma, CAR T-cell therapy has been developed to target BCMA plasma cells, which serves as a strong proof of concept for CAR T-cell therapy, Lin says. By targeting different tumor markers, CAR T-cell therapy can be expanded into other cancer types, Lin explains.

CAR T-cell therapy remains a logistically complex treatment that is still not readily available in all oncology clinics, Lin continues. These treatments must be given at specific centers that have the multidisciplinary expertise and the ability to provide this treatment, Lin concludes.